2024.05.21
On May 17, 2024, Joyo Pharmatech Co., Ltd. (“Joyo”) and Erasca, Inc. (Nasdaq: ERAS) announced that they have entered into an exclusive worldwide license agreement for the Pan-RAS(ON) Inhibitor JYP0015 program to Erasca (excluding mainland China, Hong Kong and Macau). This landmark agreement aims to enable both companies to better deliver effective and safe medical solutions to address unmet needs in patients who are diagnosed with pancreatic cancer (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and other indications.
Erasca will be granted an exclusive license to research, develop and commercialize JYP0015 worldwide (excluding mainland China, Hong Kong, and Macau). In exchange for this license, Joyo will receive an upfront payment and potential short-term payments of up to USD 20 million, up to USD 345 million in certain development and commercialization milestone payments, and tiered royalties on net sales.
Joyo researches and develops drugs for the treatment of tumors, autoimmunity, and infectious diseases. The company develops innovative drugs with global intellectual property rights based on new targets and new mechanisms of action. Currently, Joyo has one project in Phase III clinical trials, six projects/indications in Phase II clinical trials, and several other projects/indications in Phase I clinical trials or preclinical studies.
JunHe advised Joyo on the transaction structure, as well as the review, revision and negotiation of the agreements for this project. Its efficiency, rigorous professionalism, and meticulous and dedicated service have earned the trust and recognition of the client.
The JunHe team was led by partner Mr. ZHAO, Hao (Gerry) .
